Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
- Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
- Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
- Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
- Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
- High WEE1 expression is independently linked to poor survival in multiple myeloma
- Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
- The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
- FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma